Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  AbbVie    ABBV

ABBVIE (ABBV)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

AbbVie : Recent Reports from Abbvie Inc. Highlight Findings in Thiazoles (In Vitro Characterization of Ritonavir Drug Products and Correlation to Human in...

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/05/2017 | 05:57pm CET

Recent Reports from Abbvie Inc. Highlight Findings in Thiazoles (In Vitro Characterization of Ritonavir Drug Products and Correlation to Human in Vivo Performance)

By a News Reporter-Staff News Editor at Drug Week -- A new study on Thiazoles is now available. According to news reporting from North Chicago, Illinois, by NewsRx journalists, research stated, "Ritonavir (RTV) is a weakly basic drug with a pH-dependent solubility. In vitro dissolution and supersatuation behaviors of three Norvir oral products including the tablet, powder, and solution were investigated by two biorelevant dissolution methods with pH alteration: a two-stage dissolution test and a biphasic dissolution-partition test."

Financial support for this research came from AbbVie (see also Thiazoles).

The news correspondents obtained a quote from the research from Abbvie Inc., "The two-stage dissolution test revealed a high degree of supersaturation of RTV from these products accompanied by the occurrence of liquid-liquid phase separation (LLPS) in biorelevant dissolution media. Higher, stable apparent RTV concentrations were observed in the FeSSIF-V2 as compared to those in the FaSSIF-V2, which suggested a food effect with higher exposure in the fed state. This is inconsistent with the evaluation in vivo. The biphasic test revealed significantly lower degrees of supersaturation of RTV in the aqueous media from these dosage forms as compared to results of the two-stage dissolution test. RTV concentrations in octanol at 6 h obtained from the tablet and powder with the use of the biorelevant media are consistent with corresponding in vivo AUC and Cmax under the fasting and moderate fat fed (MFF) states and predict the food effect. The underlying mechanisms responsible for the food effect are also proposed. Fractional partition profiles of RTV obtained in octanol from these three Norvir oral products are in agreement with the corresponding fractional absorption profiles in vivo under both the fasting and MFF states."

According to the news reporters, the research concluded: "This study reveals a complex interplay among the dissolution, precipitation, and partition processes from these formulations that dictate the oral exposure of RTV."

For more information on this research see: In Vitro Characterization of Ritonavir Drug Products and Correlation to Human in Vivo Performance. Molecular Pharmaceutics, 2017;():. (American Chemical Society - www.acs.org; Molecular Pharmaceutics - www.pubs.acs.org/journal/mpohbp)

Our news journalists report that additional information may be obtained by contacting H. Xu, NCE-Formulation Sciences, Drug Product Development and Clinical Pharmacology and Pharmacometrics, Abbvie Inc , 1 North Waukegan Road, North Chicago, Illinois 60064, United States. Additional authors for this research include S. Vela, Y. Shi, P. Marroum and P. Gao.

The direct object identifier (DOI) for that additional information is: https://doi.org/10.1021/acs.molpharmaceut.7b00552. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

Keywords for this news article include: Antiinfectives, Antiretrovirals, Antivirals, Illinois, Ritonavir, Thiazoles, North Chicago, United States, Drugs and Therapies, Protease Inhibitors, North and Central America.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC

(c) 2017 NewsRx LLC, source Health Newsletters

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ABBVIE
04:36pABBVIE : and Voyager Therapeutics Announce Global Strategic Collaboration to Dev..
AQ
02:16pABBVIE : Announces Positive Topline Results from Phase 3 Study Evaluating Invest..
PU
02:01pABBVIE : Canadians living with Moderate to Severe Hidradenitis Suppurativa are b..
AQ
01:17pABBVIE : and Voyager Therapeutics collaborate to develop new treatments for tauo..
AQ
01:16pVOYAGER THERAPEUTICS : and AbbVie Announce Global Strategic Collaboration to Dev..
AQ
09:37aABBVIE : doubles down on tau with Voyager Alzheimer`s deal
AQ
09:22aABBVIE : steers past the wreckage, reserves $224M to kick off once-and-done gene..
AQ
08:48aABBVIE : FTC Clout Tested in Suit Versus Drugmaker -- WSJ
DJ
02/20ABBVIE : Presents New Late-Breaking Phase 2b Data on Upadacitinib in Atopic Derm..
AQ
02/20ABBVIE : Presents New Positive Late-Breaking Data from Two Phase 3 Psoriasis Tri..
AQ
More news
News from SeekingAlpha
11:49aYOUR DAILY PHARMA SCOOP : Portola Update, Wave Life Sciences To Collaborate With.. 
10:04aDividend Companies Showering Shareholders With More Cash 
08:24aAbbVie's elagolix successful in late-stage uterine fibroid study 
08:00aYOUR DAILY PHARMA SCOOP : Buy Heron At Dips, Aimmune Positive Data, Voyager And .. 
02/20Neurocrine Biosciences Shows Again That Sometimes The Tortoise Wins 
Financials ($)
Sales 2018 32 143 M
EBIT 2018 14 063 M
Net income 2018 10 488 M
Debt 2018 22 102 M
Yield 2018 2,66%
P/E ratio 2018 17,65
P/E ratio 2019 15,28
EV / Sales 2018 6,55x
EV / Sales 2019 5,95x
Capitalization 188 B
Chart ABBVIE
Duration : Period :
AbbVie Technical Analysis Chart | ABBV | US00287Y1091 | 4-Traders
Technical analysis trends ABBVIE
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 126 $
Spread / Average Target 6,7%
EPS Revisions
Managers
NameTitle
Richard A. Gonzalez Chairman & Chief Executive Officer
Azita Saleki-Gerhardt Senior Vice President-Operations
William J. Chase Chief Financial Officer & Executive Vice President
Michael E. Severino Chief Scientific Officer & Executive VP
Robert J. Alpern Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
ABBVIE16.93%188 347
MERCK KGAA-8.06%13 246
KYOWA HAKKO KIRIN CO LTD4.77%12 454
JAZZ PHARMACEUTICALS PLC8.31%8 738
ZHANGZHOU PIENTZEHUANG PHARMACEUTICL LTD14.51%6 893
CONVATEC GROUP3.26%5 818